Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics
Theorem Clinical Research
has announced the formation of a strategic alliance with
Decision Driver Analytics
(DDA) that will integrate health economics and outcomes research (HEOR), predictive modeling and definitive analysis to maximize return on investment for pharmaceutical and medical device research programs.
“The clinical studies that may prove a scientific point are really only one aspect of a successful drug or medical device development program,” said
John Potthoff, president and CEO of Theorem Clinical Research
. “Decision Driver Analytics’ product life cycle value analysis and exceptional economic insight help clients make high-value decisions with confidence throughout the entire development process.”
Decision Driver Analytics was founded in 2006 by Elizabeth Brooks, Ph.D., to provide accessible health economics analysis and strategies that can be used to drive key product decisions for manufacturers and developers. A recognized expert in her field, Brooks has designed numerous health economics models and market development programs. Backed by a team of specialists including health economists, epidemiologists, biostatisticians, medical writers and reimbursement experts, Brooks is known for an ability to make statistical results understandable and actionable.
“Knowing the right answers to key questions at critical decision points in the development process can make the difference between having the latest blockbuster or an expensive failure,” Potthoff said. “We believe this alliance helps drive projects for clients in ways that will achieve both regulatory and marketing success.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.